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SUMMARY 
 
The Col6a1-/- null mouse is a known and well characterized animal model for collagen VI 
myopathies in humans (Irwin WA, et al. 2003). Inherited mutations within the COL6 A1, 2 and 3 
genes cause the autosomal dominant or recessive Bethlem myopathy (BM), the dominant or 
recessive Ullrich myopathy (UCMD), the autosomal dominant limb-girdle muscular dystrophy 
(Scacheri PC, et al. 2002) and the recessive rare muscle myosclerosis (Merlini L, et al. 2008). 
These congenital muscular dystrophies are heterogeneous phenotypes underlined by a variety of 
COL6 genes‟ mutations. The phenotype ranges from mild and late onset myopathies (BM) to very 
severe forms (UCMD). Defective mitochondrial functions with ultrastructural alterations, increased 
spontaneous apoptosis and abnormal permeability in the transition pore (PTP) have been 
characterized both in animal models and in patients (Irwin WA, et al. 2003). 
Recently, a further link between COL6 myopathies and mitochondrial dysfunction has been 
established by the discovery that autophagy is defective in collagen VI muscular dystrophies 
(Grumati P, et al. 2010 ). This supports a mechanism of disease pathogenesis that might be due, at 
least in part, to a defect of autophagy, leading to an accumulation of abnormal mitochondria and 
sarcoplasmic reticulum. Amelioration/restoration of a proper autophagic flux in mouse models 
ameliorates these disturbances, however, despite these recent achievements, a complete 
understanding of  COL6-related diseases pathogenesis remains elusive. 
Gene expression profiling is a powerful tool for exploring the alteration of normal tissue 
transcriptional behavior in the course of disease (Shapiro E, et al. 2013 Wang SM, et al. 2013). 
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In COL6 diseases microarrays are recently employed (Paco S, et al. 2013) also to analyze the 
transcriptome of UCMD muscle and compare it to healthy muscle and other muscular dystrophies 
in order to better understand the role of collagen VI in muscle and the mechanism of disease. 
Bioinformatics analysis reveal the molecular functions and gene networks associated with collagen 
VI defects; the most significantly regulated pathways were those involved in muscle regeneration, 
extracellular matrix remodelling and inflammation, opening new insights into disease pathogenesis, 
biomarkers discovery and novel therapeutic targets. 
 
Therefore, we adopted whole genome expression profiling to study if and how the KO Col6a1-/- 
mice exhibit peculiar transcriptional patterns, which can address specific pathway alterations and 
therefore possible transcriptional biomarkers These biomarkers may be useful to better understand 
the pathogenesis of COL6 myopathies and as exploratory biomarkers of disease progression and 
drug response. 
Our studies , among the involvement of some deregulated pathways, highlighted a misregulation of 
two genes belonging to the circadian rhythm. CLOCK and EGR1 were found to be consistently 
upregulated in all KO mice analyzed, though with muscle type-dependent quantitative differences, 
being tibialis  the most affected muscle. The data was technically validated using TaqMan assays 
and customized Fluidic cards which assayed these and others circadian genes. The involvement of 
circadian genes in hereditary muscle dystrophy is fully novel, although it is already known as these 
genes are deeply involved in muscle remodeling, function, performance and aging. This new view 
opens interesting perspectives on new potential target genes involved in muscle damage 
pathogenesis. 
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AIMS 
 
The aim of this work was the identification of pre-clinical, novel genomic or proteomic biomarkers, 
which may correlate with drug response, diagnosis and disease prognosis of NMDs by determining 
genomic variations as well as defining specific transcription or protein profiles or disease-related 
pathways both in human and in suitable animal models.  
Biomarkers have been defined as cellular, biochemical, molecular alteration or biological 
characteristics that are measurable and evaluable in biological material as indicator of normal 
biological or pathogenic processes and may be used in differential and early diagnosis, in 
monitoring of disease progression, regression, or therapeutic outcome. 
One of the many approaches for biomarkers discovery is gene expression profiling which is a 
powerful tool for exploring the alteration of normal tissue transcriptional behavior in the course of 
disease (Shapiro E, et al. 2013; Wang SM, et al. 2013) Great advances in this field have been 
reached in cancer, and some deregulated transcripts are now considered prognostic/therapeutic 
biomarkers of neoplastic diseases (Lam SW et al. 2014; Cernei N. et al. 2013).  
Bioinformatics is a crucial step to understand and translate gene expression gross data and is carried 
out both by developing novel tools for data analysis, and by dedicating software to , for instance, 
whole exome sequencing ,  expression profiling or RNAsew analysis data storage,. 
Using expression profile we identified 47 genes, resulted differentially expressed in COL6 null 
mice compared to wild type mice; using a customized fluidic card we validated all these genes 
differentially expressed. Among these genes, some regulators of the circadian rhythm  process 
(Arntl, Atf5, Clock, Dbp, Egr1, Fkbp5, Per1, Per2 and Per3) were found. Some transcriptional 
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factors important for muscle-related processes (MyoD, MyoG, Mif6, Pax7) were also present 
confirming the involvement of these pathways in the COL6A1 KO mice pathology 
 
 
 
 
 
 
 
 
 
 
 
 
 
BACKGROUND 
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Rapidly expanding knowledge of neuromuscular diseases (NMDs) has provided new targets for 
disease characterization, early diagnosis and drug development whilst presenting many challenges 
about how to translate this knowledge into clinical practice. This is all the more challenging as 
initial clinical trials typically run for such a short time that it is difficult for improvement to be 
effectively measured.  
Inherited neuromuscular diseases (NMDs) are chronic degenerative diseases, each of which is 
individually rare (prevalence < 5\10.000) often associated with severe muscle weakness making 
difficult the characterization of clinical parameters. They are present in all populations and affect 
both children and adults. Most NMDs result in chronic long-term disability reduced quality of life 
and sometimes death may result from cardiac and respiratory muscle involvement and failure. The 
goal of existing management is to minimize the impact of complications such as joint or spinal 
deformity and improve cardiac and respiratory function as there currently are no curative treatments 
for any NMD. 
The aim of this work was studying the expression profile in KO COL6 mice in order to increase our 
knowledge about Collagen VI myopathies pathogenesis in the animal model. This might be also 
helping in identifying transcriptomic biomarkers of the disease profile, progression and possibly 
novel therapies monitoring. 
Biomarkers have been defined as cellular, biochemical, molecular alteration or biological 
characteristics that are measurable and evaluable in biological material as indicator of normal 
biological or pathogenic processes and may be used in differential and early diagnosis, in 
monitoring of disease progression, regression, or therapeutic outcome (http://www.bio-
nmd.eu/forPatients/). 
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 Benefits of biomarkers identification and monitoring can include: 
• Blood and urine testing may be able to replace the use of painful and invasive muscle biopsies in 
the future. 
• Diagnosis can happen earlier because testing for biomarkers is quicker and easier than genetic 
testing. 
• Disease progression can be accurately measured allowing better clinical management of 
symptoms. 
• Existing treatments (including drug dosage) can be adjusted to precisely meet the needs of 
individual patients to ensure they get the maximum benefit.  
One of the possible methods for biomarkers discovery is gene expression profiling which is a 
powerful tool for exploring the alteration of normal tissue transcriptional behavior in the course of 
disease (Shapiro E, et al. 2013; Wang SM, et al. 2013) Great advances in this field have been 
reached in cancer, and some deregulated transcripts are now considered prognostic/therapeutic 
biomarkers of neoplastic diseases (Lam SW et al. 2014; Cernei N. et al. 2013).  
Bioinformatics is a crucial step to understand and translate gene expression gross data and is carried 
both by developing novel tools for data analysis, and by dedicating software to whole exome 
sequencing analysis data storage, expression profiling and RNAseq analysis. 
 
 
 
COLLAGEN VI 
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COL6 myopathies are well defined genetic diseses which genetic defects  are well characterized, 
(Irwin W. et al. 2003) and representative of many other conditions because they include both early 
and late onset forms, fast and slow progression and severe and mild symptoms, so any biomarkers 
found may be more widely applicable.  
Collagen VI (ColVI) is an extracellular matrix (ECM) protein forming a microfilamentous network 
in several organs including skeletal muscle, skin, cornea, lung, blood vessels, intervertebral disks 
and joints (Keene DR, et al. 1998). It consists of three chains, alpha1(VI), alpha2(VI) and 
alpha3(VI), encoded by distinct genes (COL6A1, COL6A2, COL6A3, respectively). The 
alpha1(VI) and alpha2(VI) chains are about 140 kDa, while the alpha3(VI) chain has several 
alternatively spliced variants with MW of 250−300 kDa (Bonaldo P, et al. 1989; Bonado P, et al. 
1990; Chu ML, et al. 1990; Doliana R, et al. 1990;). Each chain contains a short triple helical 
domain of 335−336 amino acids and two large N− and C−terminal globular ends composed of 
repeated domains of 200 amino acids sharing similarity with the vWF−A module (Colombatti A, & 
Bonaldo P. 1991). 
ColVI has a complex pathway of intracellular assembly (Colombatti A, et al. 1987; Colombatti A, 
& Bonaldo P. 1987; Colombatti A, et al. 1995). Equimolar association of the three 
alpha−chains into a triple helical monomer is followed by formation of dimers and tetramers 
stabilized by disulfide bonds. After secretion the tetramers form a network of microfilaments with a 
typical 100−nm periodicity that bridges the surface of cells with the connective tissue (Keene DR, 
et al. 1988; Bonaldo P, et al. 1990; Kuo HJ, et al. 1997). ColVI makes a wide range of interactions 
with ECM components (Bonaldo P, et al. 1990; Kuo HJ, et al. 1997; Bidanset DJ, et al. 1992; 
Sabatelli P, et al. 2001) and cell surface receptors, including integrins and NG2 proteoglycan (Pfaff 
M, et al. 1993; Burg MA, et al. 1996). 
12 
 
ColVI is synthesized and secreted by cells organizing an ECM such as skin fibroblasts and smooth 
muscle cells, and transcriptional regulation is a key step in its production. In muscle, ColVI is 
produced both by fibroblasts and myogenic cells, and is a major component of the endomysium 
(Kuo HJ, et al. 1997) (Fig.1). 
 
 
 
Figure 1. Adapted from Bonaldo P, et al. 1990, Collagen VI location within the extracellular matrix. 
 
Deficiency of ColVI  due to mutations in the COL6 genes, causes Collagen type VI-related 
disorders.  
Collagen type VI-related disorders represent a continuum of overlapping phenotypes with Bethlem 
myopathy at the mild end, Ullrich congenital muscular dystrophy (CMD) at the severe end, and two 
rare, less well-defined disorders – autosomal dominant limb-girdle muscular dystrophy and 
autosomal recessive myosclerosis myopathy – in between. Although Bethlem myopathy and Ullrich 
CMD were defined long before their molecular basis was known, they remain useful for 
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clarification of prognosis and management (Bertini E. et al. 2011; Mendell JR et al. 2006; Bushby 
KM, et al. 2014; Lampe AK et al. 1993-2013). 
 
Normal allelic variants 
 COL6A1 comprises 37 exons (35 of which are coding) and produces a single transcript 
encoding a protein of 1021 amino acids with two C-terminal and one N-terminal vWF type 
A-like domains. 
 COL6A2 comprises 30 exons (29 of which are coding) and has been shown to produce 
multiple alternatively spliced mRNAs that differ in the 5'-untranslated region as well as in 
the 3'-coding and noncoding sequences. It produces at least three α2(VI) protein variants 
(828-1019 amino acids) with distinct carboxyl termini, which similarly contain two C-
terminal and one N-terminal vWF type A-like domain (Saitta B, et al. 1990). 
 COL6A3 comprises 44 exons (43 of which are coding) and encodes the α3(VI) chain, which 
can vary in size between 2970 and 3176 amino acids. The α3(VI) chain contains two C-
terminal vWF type A-like domains, subdomains similar to type III fibronectin repeats and 
Kunitz protease inhibitors as well as six to ten N-terminal vWF type A-like domains, thus 
contributing most of the amino-terminal globular domain of the collagen VI heterotrimer. 
Various N-terminal exons ofCOL6A3 are subject to alternative splicing and four variant 
transcripts encoding proteins with variably sized N-terminal globular domains have been 
characterized (Stokes DG, et al. 1991, Dziadek M, et al. 2002). 
 
Pathologic allelic variants 
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 Single amino acid substitutions disrupting the Gly-Xaa-Yaa motif of the highly conserved 
triple helical domain of any of the three COL6A genes (Jöbsis GJ, et al. 1996, Pepe G, et al. 
1999a, Scacheri PC, et al. 2002, Lampe AK, et al. 2005, Lucioli S, et al. 2005) constitute the 
most frequent pathogenic mechanism at 28% of the total pathogenic variants 
in COL6A1, COL6A2, and COL6A3. 
 Mutations that introduce premature termination codons (splice sites and out of frame 
deletions/insertions) form the second most frequent group at 28%. 
 Splice-site mutations that cause exon skipping occur at around the frequency (Lamande SR, 
et al. 1999, Pepe G, et al. 1999b,Pan TC, et al. 2003, Lampe et al 2005, Lucioli S, et al. 
2005), with 27% of the total. 
 Other splice-site mutations causing small in-frame deletions or insertions in regions that 
encode domains flanking the triple helical domain make up 8% of the total of pathogenic 
variants in COL6A1, COL6A2 and COL6A, with large genomic deletions appearing to be 
rare and occurring at a frequency of around 2% (Vanegas OC, et al. 2002, Lampe AK, et al. 
2005, Lucioli S, et al. 2005). 
Given the high number of mutations that result in benign amino acid changes described for the three 
genes encoding the three collagen VI peptide chains, it is difficult to be sure about the pathogenicity 
of missense mutations other than glycine substitutions within the triple helical domain. 
 
 
 
Abnormal gene product 
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 Autosomal dominant collagen type VI-related disorders. Heterozygous single amino acid 
substitutions disrupting the Gly-Xaa-Yaa motif of the highly conserved triple helical domain 
of any of the three COL6A genes (Jöbsis GJ, et al. 1996, Pepe G, et al. 1999a, Scacheri PC, 
et al. 2002, Lampe AK, et al. 2005, Lucioli S, et al. 2005), depending on their location, 
appear to either interfere with intracellular chain assembly or, following successful 
secretion, cause kinking of the tetramers, thus affecting extracellular microfibril formation 
(Lamande SR, et al. 2002). Functional haploinsufficiency via a dominant-negative effect has 
also been reported as the pathogenic mechanism for some missense and splice-site mutations 
(Lamande SR, et al. 1999). Heterozygous splice mutations (associated with autosomal 
dominant disease) leading to in-frame exonic deletions as well as in-frame genomic 
deletions preserve a unique cysteine important for dimer formation, allowing secretion of 
abnormal tetramers with a consequent dominant-negative effect on microfibrillar assembly 
(Pan TC, et al. 2003, Baker NL, et al. 2005). 
 Autosomal recessive collagen type VI-related disorders.              
Most mutations associated with autosomal recessive disease reported to date are protein-
truncating nonsense mutations. Some have been shown to result in absence of collagen VI 
because of nonsense-mediated mRNA decay (Zhang RZ, et al. 2002). 
The phenotypes associated with collagen type VI-related disorders, once thought to be distinct 
entities, were clinically defined long before their molecular basis was discovered. The collagen type 
VI-related disorders are now recognized to comprise a continuum of overlapping phenotypes with 
Bethlem myopathy at the mild end, Ullrich congenital muscular dystrophy (CMD) at the severe end, 
and two less well-defined disorders – autosomal dominant limb-girdle muscular dystrophy 
and autosomal recessive myosclerosis myopathy – in between. Although these phenotypes are now 
16 
 
recognized to overlap and fall on a continuum, these clinical designations are useful for clarification 
of prognosis and management. 
 
Bethlem Myopathy (MIM #158810) 
The onset of Bethlem myopathy ranges from prenatal to mid-adulthood. Prenatal onset is 
characterized by decreased fetal movements; neonatal onset with hypotonia or torticollis; early-
childhood onset with delayed motor milestones, muscle weakness and contractures; and adult onset 
(4th-6th decade) with proximal weakness and Achilles tendon or long finger flexor contractures 
(FIG.2). As some adults are unaware of weakness, age of onset cannot always be established. 
The contractures may come and go during childhood, but nearly all affected individuals eventually 
exhibit flexion contractures of the fingers, wrists, elbows, and ankles. These contractures can 
become disabling when combined with muscle weakness. 
Individuals can have moderate weakness and atrophy of the muscles of the trunk and limbs with 
proximal muscles being more involved than distal muscles and extensors more than flexors. 
As a result of slow but ongoing progression of the condition, more than two-thirds 
of affected individuals over age 50 years need supportive means (i.e., canes, crutches, or 
wheelchair) for outdoor mobility (Jöbsis GJ, et al. 1999, Pepe G, et al. 1999b). 
Respiratory muscle and especially diaphragmatic involvement necessitating artificial nocturnal 
respiratory support is part of the clinical spectrum but is rare and appears to be related to severe 
weakness occurring in later life (Haq RU, et al. 1999). Respiratory failure may supervene prior to 
loss of ambulation and may be associated with diaphragmatic weakness (Haq RU, et al. 1999). 
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Cardiac function is usually normal (Mohire MD, et al. 1988, de Visser M, et al. 1992). 
Missense mutations in either the triple helical or the vWF−A domains of the three COL6 genes 
were described for various BM families (Jöbsis GJ, et al. 1996; Scacheri PC, et al. 2002; Sasaki T, 
et al. 2000). Immunohistochemistry shows apparently normal or mildly reduced levels of ColVI in 
the endomysium of most BM patients. 
 
Ullrich Congenital Muscular Dystrophy (CMD) (MIM #254090) 
In addition to characteristic muscle weakness of early onset, proximal joint contractures, and 
hyperelasticity of the wrists and ankles, other features observed are congenital hip dislocation, 
prominent calcanei, and a transient kyphotic deformity at birth (FIG.2). 
With time, the distal hyperlaxity can evolve into marked finger flexion contractures and tight 
Achilles tendons (Furukawa T, & Toyokura Y. 1977; Muntoni F, et al. 2002). 
Some affected children acquire the ability to walk independently; however, progression of the 
disease often results in later loss of ambulation. 
Rigidity of the spine is often associated with scoliosis. 
Early and severe respiratory involvement may require artificial ventilatory support in the first or 
second decade of life. 
Failure to thrive is common (Demir E, et al. 2002). 
Follicular hyperkeratosis over the extensor surfaces of upper and lower limbs and keloid and 
cigarette paper scar formation are common. 
Cardiac involvement has not been documented to date. 
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Usually, UCMD shows an autosomal recessive inheritance with homozygous or compound 
heterozygous mutations in the COL6 genes. However, several cases of UCMD with dominant 
heterozygous mutations were recently reported (Pan TC, et al. 2003; Baker NL, et al. 2005; Angelin 
A, et al. 2007), and patients with a UCMD phenotype but without mutations in COL6 genes were 
also described. ColVI appears to be strongly reduced or absent in muscle biopsies from UCMD 
patients, suggesting that UCMD mutations severely affect the synthesis and secretion of ColVI 
(Camacho Vanegas O, et al. 2001; Zhang RZ, et al. 2002; Squarzoni S, et al. 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 (Lampe AK & Bushby KM. 2005). Pictures from clinical patients with Bethlem Myopathy (BM) phenotype 
from left to right; Skin follicular hyperkeratosis and distal contractures in elbows, fingers and ankle. Ullrich‟s 
Congenital Muscular Dystrophy (UCMD) phenotype from left to right; Keloid scar formation, hyperelasticity in feet 
and fingers. 
 
 
About 70 different mutations of the COL6 genes have so far been associated with UCMD and BM 
(Lampe AK, & Bushby KM. 2005) (see also http://www.dmd.nl/), but the reason why certain COL6 
mutations cause BM while others cause the more severe UCMD remains obscure. Based on the 
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partial overlap between BM and UCMD, it had been proposed that COL6 disorders represent a 
clinical continuum (Lampe AK, & Bushby KM. 2005; Pepe G, et al. 2002). 
Selective receptors directly involved in COL6 binding to muscle fibers have not yet been identified 
but the cell membrane chondroitin−sulfate proteoglycan NG2 binds COL6 (Tillet E, et al. 2002; 
Stallcup WB. 2002). NG2 has a highly regulated expression in skeletal muscle, where it is normally 
detectable in the sarcolemma of postnatal myofibers and gradually declines with age (Petrini S, et 
al. 2003). NG2 is selectively decreased in the sarcolemma of UCMD patients and Col6a1–/– mice 
(Petrini S, et al. 2005), suggesting that NG2 may represent an important molecule mediating 
ColVI−sarcolemma interactions. 
 
Other Phenotypes 
The two additional conditions included in the spectrum of collagen VI myopathies are: 
 Autosomal dominant limb-girdle muscular dystrophy (MIM #159000) caused by 
mutations in COL6A1/COL6A2 in three families andCOL6A3 in one family (Scacheri PC, et 
al. 2002). Although some affected individuals had mild weakness with only limited 
functional impairment, others had a more severe, dystrophic-like weakness with findings 
including Gower‟s maneuver, toe walking, and loss of ambulation. Joint contractures were 
either absent or much milder than those of typical Bethlem myopathy. Whereas findings of 
Bethlem myopathy are typically present in infancy, the age at onset in these three families 
ranged from infancy, to early childhood, to adulthood. 
 Autosomal recessive myosclerosis myopathy (MIM #255600) caused 
by mutation of COL6A2 in two individuals from one family (Merlini L, et al. 2008). 
Myosclerosis myopathy is characterized by difficulty in walking in early childhood, toe 
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walking, and progressive contractures of calf muscles. In the early 30s the muscles are 
slender with a firm “woody” consistency and associated with contractures that restrict range 
of motion of many joints (FIG.3A-B). By studying an Italian family affected by this rare 
disorder, we found a homozygous missense mutation in the COL6A2 gene. The mutation is 
a novel pathogenic variation of the COL6A2 gene and represents the first truncating 
mutation occurring in homozygosity in the C1 domain of the alpha2(VI) chain. By western 
blot and immunoprecipitation analysis of cell cultures from the patients, we demonstrated 
that this mutation causes the synthesis of a truncated alpha2(VI). The mutated chain is still 
able to form triple helical monomers and dimers with the other two chain, but formation of 
tetramers is strongly impaired, leading to decreased ColVI secretion. Electron microscopy 
confirmed the presence of a decreased amount of ColVI microfilaments in the ECM, 
containing abnormally−shaped tetramers (Merlini L, et al. 2008). 
 
21 
 
 
Fig.3.(A) Patient shows diffuse muscle wasting, flexion contractures of both elbows, forward abduction of shoulders, 
and flexion of fingers. There is fixed flexion of the trunk with lumbar hyperlordosis and marked flexion contractures of 
the knee and ankle joints in the left lower limb.  
(B) Transverse section of muscle biopsy from the index case (P1, left) and the affected sibling (P2, right), showing 
endomysial fibrosis, increased fatty connective tissue, variability of fiber size, and several internal nuclei. Hematoxylin 
and eosin staining. Bar, 200 _m. 
 
We have also studied biopsies and myoblasts from patients affected by COL6 muscular dystrophies. 
UCMD patients display an increased rate of apoptosis in skeletal muscle in vivo and in primary 
myoblast cultures (Angelin A, et al. 2007). The latter also displayed a measurable fraction of altered 
mitochondria, with morphological alterations ranging from shape changes to overt swelling; and the 
presence of a latent mitochondrial dysfunction that could be revealed by the addition of oligomycin, 
which caused depolarization only in mitochondria from patients (Angelin A, et al. 2007).  The 
mitochondrial defect could be revealed in cultures from UCMD patients irrespective of whether the 
primary genetic defect was in the COL6A1 or COL6A3 gene, and both in homozygous and 
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heterozygous mutations (Angelin A, et al. 2007).  Remarkably, PTP desensitization could be 
obtained also with MeAla3EtVal4−cyclosporin (Debio 025), a specific CyP inhibitor that 
desensitizes the PTP through mitochondrial CyP−D but has no inhibitory effects on calcineurin and 
therefore no immunosuppressive activity (Hansson MJ, et al. 2004). These findings suggest that 
PTP opening plays a key role in all COL6 myopathies and open new perspectives for the 
pharmacological treatment of patients. 
Currently the only available animal model of COL6 muscular dystrophies is a mutant mouse with 
targeted inactivation of the COL6A1 gene in embryonic stem cellsby targeted gene disruption with 
a vector containing neomyvin resistance cassette in the second exon (Bonaldo P, et al. 1998). 
Homozygous null (Col6a1–/–) mice completely lack COL6 because in the absence of the 
alpha1(VI) chain COL6 does not assemble. Col6a1–/– mice are affected by an early onset 
myopathic disease with muscle weakness and histological changes that are similar to those detected 
in BM and UCMD patients (Bonaldo P, et al. 1998; Irwin WA, et al 2003). Ultrastructural analysis 
revealed the presence (in about 30% of the fibers) of marked dilations of the sarcoplasmic reticulum 
(SR), and of mitochondrial alterations that ranged from tubular cristae, to electron−dense 
inclusions, to overt swelling (Irwin WA, et al 2003). Remarkably, myofibers with 
mitochondrial−SR alterations also displayed nuclear features of apoptosis, suggesting a link 
between organellar changes and increased incidence of cell death (fig.4).  
However, has been demostrated that an other pathway correlated with abnormal mitochondria and 
involved in myopathy is an autophagic pathway; indeed a major autophagic effector protein, beclin-
1, is reduced in Col6a1−/− muscles. Thus, beclin-1 seems to be necessary and sufficient for basal 
autophagy and for its correct induction (Grumati P, et al. 2010). 
23 
 
 
 
 
Fig. 4: Ultrastructural defects in collagen VI−deficient muscles (Irwin WA, et al. 2003). Electron micrographs of 
diaphragm and FDB muscles from wild-type (a,c,f,h) and Col6a1
-/-
 (b,d,e,g,i) mice. (a,b) Low-power view of FDB 
longitudinal sections showing alterations in SR (arrows) and mitochondria (arrowheads) in Col6a1
-/-
 fibers. Myofibrillar 
network is comparable in Col6a1
-/-
 and wild-type mice. (c−e) High-power view of diaphragm transverse sections 
showing abnormal mitochondria (Mit) with altered cristae and dense bodies (white arrow) in Col6a1
-/-
 fibers. 
Sarcolemma and basal lamina appear normal (arrowheads and inset in e). (f,g) High-power view of the triadic system 
showing dilation of the terminal cisternae of SR and normal T-tubules (arrowheads) in Col6a1
-/-
 fibers. Swelling is 
visible in some Col6a1
-/-
 mitochondria (asterisk). (h,i) Peripheral chromatin condensation and irregular shape 
characteristic of apoptosis are detected in Col6a1
-/-
 myonuclei (Nu). 
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MAIN PUBLICATIONS DURING PHD 
 
 
During my PhD I have contributed to the definition of col6-related disorders, which are a 
heterogeneous group of congenital myopathies, in order to increase both our knowledge about 
Collagen VI myopathies pathogenesis and the identification of specific transcription or protein 
profiles or disease-related pathways both in human and in suitable animal models. 
First step of this huge work has been the identification of the suitability of peripheral blood 
macrophages as a reliable, minimally invasive tool for supplementing or replacing muscle/skin 
biopsies in the diagnosis and monitoring of collagen VI-related myopathies (Gualandi F, et al. 
2011); In the dominant BM patient, no collagen VI alterations were detectable in macrophages or 
muscle biopsy but in the remaining patients, the protein defect caused by the selected mutations, as 
well as the transcriptional abnormalities, were readily detectable in macrophages, at levels 
comparable to those observed in muscle biopsy samples and cultured skin fibroblasts.  
Interestingly two additional collagen VI chains were identified in humans, the α5 and α6 chains 
(Sabatelli P, et al. 2012): results showed a restricted and differential distribution of the novel α6 and 
α5 chains in skeletal muscle when compared to the widely distributed, homologous α3 chain, 
suggesting that these new chains may play specific roles in specialized ECM structures. While the 
α5 chain may have a specialized function in tissue areas subjected to tensile stress, the α6 chain 
appears implicated in ECM remodeling during muscle fibrosis. 
A case report has also been described (Martoni E, et al. 2013) focusing the attention on mutations 
within the C-terminal region of the COL6A1 gene where they were only detected in 
Ullrich/Bethlem patients on extremely rare occasions. Two Brazilian brothers with a classic Ullrich 
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phenotype and compound heterozygous for two truncating mutations in COL6A1 gene, were 
expected to result in the loss of the α1(VI) chain C2 subdomain. Despite the reduction in COL6A1 
RNA level due to nonsense RNA decay, three truncated alpha1 (VI) chains were produced as 
protein variants encoded by different out-of-frame transcripts. Collagen VI matrix was severely 
decreased and intracellular protein retention evident. The altered deposition of the fibronectin 
network highlighted abnormal interactions of the mutated collagen VI, lacking the α1(VI) C2 
domain, within the extracellular matrix. 
More recently we have identified a new form of extracellular matrix-related myopathy (Hicks D, et 
al. 2014); it was already known that should be additional causal genes to identify as in ∼50% of BM 
cases no mutations in the COL6 genes are identified. In a cohort of -24 patients with a BM-like 
phenotype, we first sequenced 12 candidate genes based on their function, including genes for 
known binding partners of collagen VI, and those enzymes involved in its correct post-translational 
modification, assembly and secretion. Proceeding to whole-exome sequencing (WES), we identified 
mutations in the COL12A1 gene, a member of the FACIT collagens (fibril-associated collagens 
with interrupted triple helices) in five individuals from two families. Both families showed 
dominant inheritance with a clinical phenotype resembling classical BM. Abnormality at the protein 
level was confirmed in both families by the intracellular retention of collagen XII in patient dermal 
fibroblastsWe conclude that the spectrum of causative genes in extracellular matrix (ECM)-related 
myopathies be extended to include COL12A1. 
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METHODS 
 
Samples selection  
Four mice of six months of age for each condition (wild type and knock out) were selected and total 
RNA was extracted and pooled per muscle type: diaphragm, gastrocnemius and tibialis. 
 
RNA extraction 
Total RNAs was extracted from tibialis, diaphragm and gastrocnemius muscle tissue of WT and KO 
mice by using TRIzol Reagent (Invitrogen). Tissues were homogenized in 1 ml of TRIzol and 
incubated for 5‟ at room temperature to permit the complete dissociation of nucleoproteins 
complexes. 200 µl of chloroform were added and tubes were incubated for 3‟ at room temperature. 
After centrifugation (12000 g x 15‟ at 4°C) the mixture separated in a lower red, phenol-chloroform 
phase, an interphase and a colorless upper aqueous phase containing RNA. RNA from each muscle 
was purified with TRIzol Plus RNA Purification Kit (Invitrogen) and quantified by means of a 
Nanodrop (Thermo scientific) spectrophotometer and evaluated for the integrity with a 2100 
Bioanalyser (Agilent) prior to be pooled in the same amount for muscles of the same kind. 
 
 
Whole genome expression microarray analysis 
To analyse the transcriptional profile in the mouse samples available, we selected the Whole Mouse 
Genome gene expression kit composed by four arrays of 44000 probes (Agilent Technologies, 
G4122F). 
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Sample labeling and hybridization were performed in triplicate according to the protocols provided 
by Agilent (One-Color Microarray-Based Gene Expression Analysis version 5.0.1). The array was 
analyzed using the Agilent scanner and Feature Extraction software (v9.1). Quality of the results 
was verified via Agilent Quality Controls (Spike-in), consisting of a mixture of 10 in vitro-
synthesized, polyadenylated transcripts derived from the Adenovirus E1A gene, premixed at 
concentrations spanning six logs and differing by one-log or half-log increments. 
Data analysis was performed using GeneSpring GX v.11. Data were normalized and log 
transformed. Unreliable “flagged” probes were excluded from further analysis. 2wayANOVA were 
performed for WT vs KO muscles with p<0.05 and Benjamini-Hochberg correction for multiple 
testing followed by fold change analysis (cut-off >3.0). Gene Ontology (p<0.01) was performed to 
group the differentially expressed genes into three main domains: cellular component, molecular 
function and biological process. 
 
 
Microarray data analysis validation by fluidic cards 
Following the pathway‟s bioinformatics analysis, 46 genes have been selected which resulted both 
differentially expressed between wild type and KO mice, in addition we analyzed Beclin-1 as 
candidate gene from literature data. The 47 selected genes predominantly include circadian pathway 
and muscle regeneration, but also known genes involved in autophagy and apoptosis. These genes 
were used to design customized TaqMan systems based on the Applied Biosystems database in 
order to set up a TaqMan low density array (TLDA or Fluidic card). The Fluidcard was used to 
validate the results obtained using the microarray platform. One gene (Mip) was selected as 
negative control for its absence of expression in the microarray data. 
The fluidic card format 48, able to analyze 48 genes (47 test and the 18S housekeeping gene) 
simultaneously in eight samples, was run five times for each sample. 
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A total of 150 ng for each pool was retrotranscribed by means of a High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems), according to the manufacturer's instructions to be loaded in 
a single port of the TLDA and run on an ABI 7900HT System (Applied Biosystem) for 2 min at 50 
°C, 10 min at 95 °C, followed by 40 cycles for 15 s at 97 °C and 1 min at 60 °C. 
Data analysis was performed following the ∆∆CT Method (Applied Biosystems User Bulletin #2) 
and using the 18S gene as calibrator and the WT samples as controls in respect to the KO samples. 
The mean 2-DDCT obtained has been Log transformed to be compared with the normalized fold 
change microarray data (raw data table).  
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RESULTS 
 
To analyze the transcriptional profile in the KO Col6a1
-/-
 mice as compared to WT mice we 
selected the Whole Mouse Genome gene expression kit (Agilent Technologies, G4122F) which is 
composed of four arrays and a total of 44000 probes. Gene expression profiles were analyzed in 
three muscle types; diaphragm, tibialis and gastrocnemius. 
 
Data processing 
Only 6-months-old mice were included in analysis and intensity data with local background 
adjustment by spatial detrending was extracted from Agilent files. This resulted in 45018 probes 
and 48 samples. Synonymous probes (which match to the same gene) were averaged. The final 
dataset consisted of 28052 probes. Additionally, data was log-transformed. 
Quantile between-array normalization was utilized to make distributions of probes equal for each 
array. Box plot for probe distribution for each array before and after normalization is shown in fig 
5. 
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Fig 5: Data normalization 
 
To perform multi-way comparisons in complex experiment design we utilized limma package 
(Wettenhall JM, & Smyth GK. 2004). This package fits separate linear model for each gene and 
uses moderated t-statistics to estimate differences between arrays. Empirical Bayes analysis is used 
to improve statistical power in small sample sizes. For each gene we fitted linear model with zero 
intercept parameterization because of the factorial design of the experiment. Corresponding p-
values were corrected for multiple testing using Benjamini & Hochberg approach (Benjamini & 
Hochberg, 1995). 
All data analysis and graphics were performed using free R statistical language (www.r-project.org) 
and set of bioinformatics-related packages, Bioconductor (www/bioconductor.org), Matlab and 
Ariadne Pathway Studio (ResNet8). 
 
Samples clustering 
A gene cluster analysis of the expression profiles in each muscle type samples in both the KO and 
WT mice was performed. We utilized complete linkage hierarchical clustering coupled with 
Spearman correlation as a distance measure. The resulting dendrogram is shown in figure 6. The 
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expression profiles of KO and WT gastrocnemius were most similar and thus clustered together.  
Those of diaphragm were also fairly well correlated and clustered together, although they were 
significantly different than the patterns seen in gastrocnemius. Interestingly, the expression profiles 
of KO vs. WT tibialis were most varied; with the profile of WT clustering with those gastrocnemius 
and that of the KO tibialis clustering with diaphragm. 
 
 
Fig 6: Data clusterization 
 
Significant genes selection 
To determine those genes that were significantly differentially expressed (p-value < 0.05, limma 
package) we analyzed each muscle type separately and in “pooled” tissue (averaged expression 
change over all muscle types).  
The tissue most affected by col6 knockout is tibialis with 11170 differentially expressed genes. 
Diaphragm is second with 6790 differentially expressed genes and the least affected is 
gastrocnemius (3759 genes) . 
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KO vs WT effect 
We applied “Find Go groups enriched with selected entities: cellular component” tool to genes with 
p-value <0.05 and chose top 10 significant (p-value <0.05) results by overlap for each muscle and 
for pooled dataset to ascribe differentially expressed genes to cellular components (tab. 1).  
 
% of genes assosiated with 
cellular component 
Muscle Type 
Cellular Component Tibialis Diaphragm Gastrocnemi
us 
All 
membrane 26% 24% 23% 23% 
cytoplasm 24% 22% 20% 22% 
nucleus 23% 22% 18% 21% 
plasma membrane 12% 12% 11% - 
cytosol 8% 8% 6% 5% 
mitochondrion 8% 8% 6% 7% 
extracellular region 8% 8% 8% 7% 
endoplasmic reticulum 6% 5% 5% 4% 
integral to plasma membrane 5% 4% 4% - 
Golgi apparatus 4% 4% 4% 3% 
extracellular space 4% 4% 4% - 
cytoskeleton 4% 3% 3% 4% 
proteinaceous extracellular 
matrix 
1% 1% 2% 3% 
 
Tab 1. differentially expressed genes associated to cellular components 
 
Muscles comparison 
Genes associated with muscle development and function displayed altered expression in Col6-/- 
mice. These changes affected multiple aspects of muscle biology including structure, metabolism, 
transcription and regulation and varied between the tested muscle types. 60% (26 out of 44) of 
muscle-specific genes change their expression in an opposite direction when comparing tibialis to 
diaphragm, 23% between tibialis and gastrocnemius (7 out of 30) and 67% between gastrocnemius 
and diaphragm (12 of 18) (each set filtered by pvalue KO vs WT mice 0.05) (Fig.7). 
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Fig. 7.  each set filtered by p-value KO vs WT mice 0.05  in diaphragm, tibialis and gastrocnemius muscles 
 
Below is the cluster analysis of non-filtered muscle-related genes in different muscle types (fig. 8).  
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Fig. 8: Muscle-related genes KO vs WT 
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Comparing to other muscle types Tibialis displayed differential expression of variant myosin, 
troponin and calsequestrin isoforms (predominantly cardiac and slow), and increased expression of 
PAX3. Genes, differentially expressed in diaphragm and tibialis, are almost all members of the 
dystrophin-glycan complex (dystrophin, dystrobrevin, dystroglycan 1, syntrophin, α-, β-, γ-
sarcoglycans) and several transcriptional factors important for muscle-related processes, such as 
MYOD1, MYOG, MYF6, NFATC2, PAX7. In diaphragm embryonic isoforms of myosin are up-
regulated, which can be regarded as a sign of regeneration as well as up-regulated PAX7, a marker 
of satellite cells activity. 
Differentially expressed genes 
The majority of gene expression changes in KO vs. WT mice differ for the different muscle types. 
Direct inspection of all genes displaying significant changes in expression level with the same sign 
in all tissues identified a relatively small subset of only 479 genes. This small number of consistent 
changes in expression corresponds to the high heterogeneity of effects that the col6 mutation has in 
the different muscle groups. Gene set enrichment analysis of these 479 genes was employed to 
identify those gene ontology (GO) groups with the most significant (p < 0.05) level of consistent 
change. The top 10 GO groups are listed in Table 2. 
479 genes have the same sign effect in KO vs WT with p-value 
<0.05 in each muscle 
Up  Down  
inflammatory response 18 1 
positive regulation of cell proliferation 10 9 
regulation of transcription 33 12 
hydrolase activity 21 22 
transferase activity 19 21 
modification-dependent protein catabolic process 8 7 
GTPase activity 7 6 
cholesterol metabolic process 5 1 
positive regulation of mast cell cytokine production 3 0 
positive regulation of integrin activatioin  1 1 
Tab.2: The top 10 GO groups 
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Unfortunately, the majority of the GO groups identified are somewhat vague and not specific 
enough to yield insight regarding the effects of the col6 KO. Thus, we further probed the composite 
gene expression profile of the "pooled" data from all muscle groups, which indicated 334 relevant 
genes. Gene set enrichment analysis of these 334 genes identified a different subset of GO groups 
(Table 3). 
334 genes are significantly different for pooled muscles in KO vs 
WT 
Up  Down  
rhythmic process  0  6  
nuclear localization sequence binding  0  3  
retinol metabolic process  0  3  
regulation of transcription  17  9  
ATP binding  10  14  
Wnt-protein binding  2  1  
response to cadmium ion  1  2  
thyroid hormone generation  2  0  
transport  7  11  
apoptosis  4  5  
Tab. 3: different subset of GO groups from “pooled” data 
The intersection of two lists above has 94 genes with the following GO groups enriched (tab. 4): 
Intersected 94 KO vs WT genes Up Down 
transferase activity 7 8 
negative regulation of signal transduction 2 1 
negative regulation of ubiquitin-protein ligase activity 
involved in mitotic cell cycle 
0 3 
response to lead ion 1 1 
transcription factor activity 5 4 
Tab. 4: intersection of the two lists 
It is clear that if data from different muscles are pooled, there are not so many inflammatory genes 
that have significant expression change between KO and WT mice. This leaded us to conclusion 
that inflammatory genes are most variable between different muscle types, so they are probably not 
suitable biomarkers. 
Interestingly, one of the top 10 GO groups selected was "rhythmic process" which is a set of genes 
that are involved in the regulation of circadian rhythms. 
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Significant regulators 
For further identifying key regulators that might affect or be effected in col6 disease, we employed 
sub-network enrichment analysis (SNEA) using Pathway Studio (Elsevier). SNEA utilizes literature 
(ResNet) and experimentally determined data to define the relationships between all molecular 
entities within the cell. In this way key pathways, either upstream or downstream, of identified gene 
expression changes can be elucidated and thus provide insight into potential key regulators of an 
altered cellular process. Again we performed this analysis on both the expression profiles of each 
muscle group individually as well as in the "pooled" dataset. Furthermore, we explored the 
intersection of these two datasets. For this initial SNEA experiment we used the Fisher Exact test as 
a measure of statistical significance. Identified key regulators are presented in figure 9. 
  
 
Fig. 9. Regulators of KO vs WT significant genes: each muscle group individually (blue highlight; “pooled” dataset 
yellow highlighted and the intersection red highlighted) 
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Genes with similar effect, but different base levels in different muscle groups are primarily 
regulated by inflammatory cytokines and receptors. In the "pooled" dataset a large number of key 
regulators for the most stable group of differentially expressed genes are regulators of cellular 
circadian rhythm (ARNTL, CLOCK, PER1, PER3) in good agreement the prior GO analysis. 
Unsurprisingly, identified regulators for the intersection of the two datasets shows features of the 
both previous groups, with the following intersecting genes: CLOCK, ARNTL, GFI1B, IL2, 
cytokine, CD28, PIM3. In total 47 key regulators were selected. 
To verify the selected key regulators, we used additional statistical procedures within the Pathway 
Studio software (sub-network enrichment analysis with Mann-Whitney test, p-value 0.05, top 100 
regulators) to verify potential regulators of the observed expression changes. All log ratio values 
KO vs. WT in the 3 muscle groups and the “pooled” dataset were used. Data was filtered to accept 
only gene expression changes with p-values <0.05 and used SNEA afterwards. This procedure gave 
us 8 different ranking lists (Table 5). Regulators, found in at least 4 of these ranking lists are 
presented below. Only two of the SNEA regulators were found more than 4 times – GH1 and, 
again, CLOCK. Noteworthy, none of the most common regulators is significant for gastrocnemius 
muscle. 
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Rank 
value 
All All (diff. 
exp 
pval<0.05) 
Diaphragm Diaphragm 
(diff. exp 
pval<0.05) 
Gastrocnemius Gastrocnemius  
(diff. exp 
pval<0.05) 
Tibialis Tibialis  
(diff. exp 
pval<0.05) 
Total 
Sum 
of # 
GH1 8  15 5   3 3 34 
CLOCK  2 26 21   19 28 96 
HNF4A   1 1   1 1 4 
HNF1A   2 2   2 2 8 
NR1H4   5 6   4 4 19 
NR1I3   3 10   8 5 26 
PPARA   7 8   5 11 31 
FOXA2   4 4   16 8 32 
CEBPA   9 7   9 10 35 
RXRA   14 11   13 9 47 
retinoid-X receptor 21 18   6 6 51 
NR1I2   8 17   14 14 53 
IL6   22 15   12 7 56 
HNF1B   16 13   15 15 59 
GCG   13 16   17 20 66 
HNF4G   10 14   26 22 72 
FOXM1   6 3   44 23 76 
LXR   19 31   10 17 77 
NR1H3 9  53    11 18 91 
CEBPB   30 30   18 13 91 
NR   23 20   33 16 92 
ONECUT1  11 12   35 35 93 
nuclear hormone 
receptor 
25 24   20 27 96 
NR0B2   20 26   30 32 108 
FOXA3   31 29   24 25 109 
fibrinogen  28 36   29 21 114 
SREBF1   48 49   7 12 116 
NR5A2   38 35   23 24 120 
NR3C1   36 38   28 19 121 
THRB   39 27   49 31 146 
F9   32 37   38 41 148 
INS   51 25   37 40 153 
FABP1   40 63   96 43 242 
DBP   58 50   61 80 249 
FGF21   45 52   64 93 254 
 
Table 5: ranking list  
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Among the possible pathways of expression changes it seems that circadian rhythm is one of the 
most affected circuit (significant GO group, CLOCK and ARNTL as regulators found by several 
statistical procedures). We used corresponding sub-networks found above to construct a possible 
circadian pathway (Fig. 10). 
 
 
 
Fig 10: CLOCK ARNTL pathway. Highlighted - differentially expressed genes KO vs WT in pooled tissue sample 
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Microarray data analysis validation (fluidic card) 
To validate the 47 selected key regulators, we again explored the differential expression of these 
proteins using Taqman low-density array (TLDA) cards (Fig. 11). 
 
 
Fig 11: Fluidic card design  
 
Comparison of the data obtained from both the microarray experiments and those with the TLDA 
cards resulted in the same sign and trend of fold change in 37 out of 44 genes (84%) in the 
diaphragm and tibialis tissues, whereas in the gastrocnemious we found 32 out of 44 (75%) of genes 
with these characteristics (fig.12) 
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Fig 12. representation of non validated/validated genes in the three tissues. 
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However, a number of genes (Ccr5, Gh1, Ifng, Il6ra, Il2, Prl and Socs1) for which a significant 
fold-change was detected by the microarray, were poorly or not at all detected by the TLDA card. 
The Csf3 gene was only detected by the TLDA in tibialis muscle. 
 
Up-regulated and down-regulated genes as detected by the TLDA cards in KO vs. WT mice are 
presented in figure 12. Negative control genes, Mip and Col6a1, were undetectable or down-
regulated, respectively, for both methods in all three muscle types representing a true negative 
control. The TLDA and microarray data were in good agreement for regulators of the rhythmic 
process (Arntl, Atf5, Clock, Dbp, Egr1, Fkbp5, Per1, Per2 and Per3) and transcriptional factors 
important for muscle-related processes (MyoD, MyoG, Mif6, Pax7) in both diaphragm and tibialis 
and to a lesser extent in gastrocnemious confirming the involvement of these pathways in the 
Col6a1 KO mice (fig. 12).   
We confirmed the down regulation of Beclin-1, as reported by Grumati P. et al., in KO vs WT mice 
in all 3 muscle tissues analyzed, even though this deregulation does not appear significantly 
relevant. 
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DISCUSSION 
 
Collagen VI myopathies are a heterogeneous group of inherited diseases caused by mutations in 
COL6A genes. It has been previously identified a latent mitochondrial dysfunction in myoblasts 
from patients which displayed altered mitochondria and increased occurrence of spontaneous 
apoptosis.  
The Col6a1-/- null mouse is a known and well characterized animal model for collagen VI 
myopathies in humans (Irwin WA, et al. 2003). Inherited mutations within the COL6 A1, 2 and 3 
genes cause the autosomal dominant or recessive Bethlem myopathy (BM), the dominant or 
recessive Ullrich myopathy (UCMD), the autosomal dominant limb-girdle muscular dystrophy 
(Scacheri PC, et al. 2002) and the recessive rare muscle myosclerosis (Merlini L, et al. 2008). 
These congenital muscular dystrophies are heterogeneous phenotypes underlined by a variety of 
COL6 genes‟ mutations. The phenotype ranges from mild and late onset myopathies (BM) to very 
severe forms (UCMD). Defective mitochondrial functions with ultrastructural alterations, increased 
spontaneous apoptosis and abnormal permeability in the transition pore (PTP) have been 
characterized both in animal models and in patients (Irwin WA, et al. 2003). The PTP abnormalities 
are reverted by inhibition of the pore via Cyclosporine A (CsA) treatment. Proof of principle of 
these effects of CsA have been demonstrated in vitro as well as in animal models and has 
subsequently been translated into a pivotal clinical trial (Angelin A, et al. 2007). 
Recently, a further link between COL6 myopathies and mitochondrial dysfunction has been 
established by the discovery that autophagy is defective in collagen VI muscular dystrophies 
(Grumati P, et al. 2010). This supports a mechanism of disease pathogenesis that might be due, at 
least in part, to a defect of autophagy, leading to an accumulation of abnormal mitochondria and 
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sarcoplasmic reticulum. Amelioration/restoration of a proper autophagic flux in mouse models 
ameliorates these disturbances, however, despite these recent achievements, a complete 
understanding of  COL6 disease pathogenesis remains elusive. 
However in our data, beclin-1, a major autophagic effector protein, does not appear to be 
significantly deregulated suggesting the involvement of other candidated pathways in the 
pathophysiological mechanism of Col6 related myopathies.  
 
Skeletal muscle biopsy is a choice method to monitor disease progression and the effects of 
treatments; however, it is an invasive and painful method and requires surgical expertise. Cultured 
skin fibroblasts are currently used to evaluate the expression pattern of collagen VI in UCMD/BM 
patients. However, cultured fibroblasts are not useful for functional studies since they do not display 
the characteristic mitochondria alterations.  
Gene expression profiling is a powerful tool for exploring the alteration of normal tissue 
transcriptional behavior in the course of disease (Shapiro E, et al. 2013 Wang SM, et al. 2013). 
Great advances in this field have been reached in cancer, and some deregulated transcripts are now 
considered prognostic/therapeutic biomarkers of neoplastic diseases (Lam SW et al. 2014. Cernei 
N. et al. 2013).  
Animal models do represent an established model to study expression profile in human diseases, 
including muscular dystrophies and muscle pathologies („t Hoen PA, et al. 2006; Marotta M, et al. 
2009). 
In COL6 diseases microarrays are recently employed (Paco S, et al. 2013) also to analyze the 
transcriptome of UCMD muscle and compare it to healthy muscle and other muscular dystrophies 
in order to better understand the role of collagen VI in muscle and the mechanism of disease. 
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Bioinformatics analysis reveal the molecular functions and gene networks associated with collagen 
VI defects; the most significantly regulated pathways were those involved in muscle regeneration, 
extracellular matrix remodelling and inflammation, opening new insights into disease pathogenesis, 
biomarkers discovery and novel therapeutic targets. 
 
We adopted whole genome expression profiling to study if and how the KO Col6a1-/- mice exhibit 
peculiar transcriptional patterns which can address specific pathway alterations and therefore 
possible transcriptional biomarkers. These biomarkers may be useful to better understand the 
pathogenesis of COL6 myopathies and as exploratory biomarkers of disease progression and drug 
response. 
To analyze the transcriptional profile in the KO mice compared to WT we used the whole mouse 
genome expression kit (Agilent technologies G4122F) in three different muscular district: tibialis, 
diaphragm and gastrocnemius of mice of six months of age. We differentiated our analysis studying 
those genes that were significantly differentially expressed in each muscle type both separately and 
in “pooled” tissues (all tissues taken together as one) and among the three muscles analyzed, tibialis 
and diaphragm seemed to be the most affected whereas gastrocnemius showed only few differences. 
We identified changes in genes associated with muscle function including structure, metabolism, 
transcription and regulation and varying between the tested muscles. 
The number of genes significantly changed in all tissues analyzed both separately and “pooled” 
together with the same sign of effect is relatively small, 479 genes and 334 genes respectively; gene 
set enrichment of these genes was employed to  identify a list of top GO groups, one for tissues 
analyzed separately and one for “pooled” muscles. The intersection of these two GO groups 
allowed us to conclude that inflammatory genes (found at the top of GO group of genes analyzed 
separately as inflammatory response) are probably not suitable transcriptomic biomarkers; they 
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disappear in prioritization after the GO intersection. On the contrary one of the top GO groups, 
maintained after intersection,  was “rhythmic process” which is a set of genes involved in circadian 
rhythm regulation. 
In order to further refine the transcriptomic signature, we employed a sub-network enrichment 
analysis again on both separate tissues and  “pooled” ones. Furthermore we explored again the 
intersection of the two dataset. In total 47 key regulators were selected. 
To verify the selected key regulators we used an additional statistical procedures, data was filtered 
several times giving us 8 ranking lists; regulators found at least in four of these ranking lists have 
been taken and just two regulators were found more than four times: CLOCK and GH1. 
Among the possible mechanism of expression it seems that circadian rhythm is one of the most 
affected (significant GO groups and CLOCK and ARNTL s regulators found by several statistical 
procedures). 
 
To validate the 47 selected key regulators we explored again the differential expression of these 
transcripts  using low-density array cards (fluidic cards); fluidic cards and microarray data were in 
good agreement for: 
 Regulators of the circadian rhythm process (Arntl, Atf5, Clock, Dbp, Egr1, Fkbp5, Per1, 
Per2 and Per3). 
 Transcription factors important for muscle related process (MyoD, MyoG, Mif6, Pax7). 
All these genes were deregulated both in diaphragm and in tibialis and lower in gastrocnemius. 
Interestingly, in null COLVI mice the expression profile was slightly moved toward the up-
regulation respect to the down-regulation suggesting a possible gain of function of the involved 
genes rather than a loss of function. 
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In summary our studies revealed a clear involvement of two genes known to be controlling the 
circadian rhythm, CLOCK and EGR1 found to be consistently upregulated in all KO mice analyzed, 
although with muscle-type dependent quantitative differences. Tibialis is the muscle most affected. 
The graphs below show the gene expression microarray data analysis (blue) and the fluidic cards 
validation (red) for each muscle (Fig.13).  
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Fig 13.  gene expression microarray data analysis (blue) and the fluidic cards validation (red) for each muscle in 
circadian pathway 
 
The involvement of circadian genes in hereditary muscle dystrophy is fully novel, although it is 
already known that these genes are deeply involved in muscle remodeling, function, performance 
and aging (Andrews JL, et al. 2010; McCarthy JJ, et al. 2007). This new view opens interesting 
perspectives on new potential target genes involved in muscle damage pathogenesis and potentially 
a cure. 
Circadian rhythms are approximate 24 hours (24-h) behavioral and physiological cycles that 
function to prepare an organism for daily environmental changes. 
The basic clock mechanism is a network of transcriptional-translational feedback loops that drive 
rhythmic expression of genes over a 24-h period. The cycles are endogenously generated self-
sustaining rhythms but can be influenced, in mammals, by environmental stimuli such as light and 
feeding (Ko CH. Et al, 2006, Levi F. et al. 2007, Shibler U. 2005). The temporal coordination 
between endogenous cellular rhythms and the environment has been experimentally shown to 
provide an adaptive advantage by enhancing an organism‟s ability to anticipate daily changes in 
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light, temperature, and humidity (Woelfle MA. Et al, 2004). The molecular mechanism regulating 
circadian rhythms is described as a network composed of transcriptional-translational feedback 
loops and is referred to as the core clock (Lowrey PL. et al, 2004, Sangoram AM. et al, 1998). The 
positive loop of the core clock is formed by two members Clock (circadian locomotor output 
control kaput), and Bmal1 (brain muscle arnt-like 1). The CLOCK:BMAL1 heterodimer activates 
transcription of additional core clock genes Period (Per1, Per2, and Per3) and Cryptochrome (Cry1 
and Cry2). The CRY and PER proteins constitute the negative loop of the core clock by forming a 
multimeric complex that inhibits CLOCK:BMAL1 activity upon translocation to the nucleus. The 
orphan nuclear receptors Rev-erb_, Rev-erb_, and Rora (RAR-related orphan receptor alpha) are the 
remaining core clock genes and are interwoven into the core clock mechanism via their action in 
repressing and activating Bmal1 gene transcription, respectively (Akashi M, et al. 2005, Lowrey PL. 
et al, 2004, Sato TK, et al. 2004, Ueda HR. et al, 2002) (Fig 14). 
 
 
Fig. 14: schematic representation of circadian rhythm 
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We have provided, at least in part, the evidence that the core regulators of the circadian rhythm are 
deregulated in Col6a1
-/- 
mice versus WT, highlighting a possible link between NMDs and circadian 
oscillators to be further and deeper clarified. 
Expression profile has already been employed to determine the circadian transcriptome of adult 
mouse skeletal muscle. (McCarthy JJ, et al. 2007). Identifying genes associated with regulation of 
transcription, protein synthesis and degradation, and lipid metabolism illustrating the fundamental 
role that the core clock plays in maintaining cellular homeostasis. Few genes were identified as 
having a circadian pattern of expression in adult skeletal muscle: among of these Arntl 1 (Bmal1) 
Period 2 (Per2) transcript levels oscillate over 48h with a circadian period in adult skeletal muscle 
(Fig.15). 
 
 
 
Fig 15. Arntl 1 (Bmal1) Period 2 (Per2) transcript levels oscillate over 48h with a circadian period in adult skeletal 
muscle (McCarthy J et al, 2007) 
 
 
 
Clock mutant shown also an altered expression  of circadian genes and MyoD, a known 
transcription factor key regulator of muscle differentiation; the identification of Myod1 as a 
circadian gene was an exciting finding because it expands the potential function of Myod1 beyond 
its known role in myogenesis to include an active role in the daily maintenance of adult skeletal 
muscle.  
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The circadian expression of Myod1 transcript may be conserved between mouse and human as 
suggested by a recent study that found daily variation in Myod1 expression in human skeletal 
muscle (Vissing K, et al. 2005). The circadian function of Myod1 remains to be determined, but the 
possible conservation of Myod1 circadian expression between species indicates an important role in 
skeletal muscle.  
It is important to note that we have also found MyoD as a deregulated gene into GO group of 
transcriptional factors important for muscle related processes among those validated by fluidic 
cards. 
MyoD is a master regulator of myogenesis and exhibits a circadian rhythm in its protein and RNA 
levels suggesting a possible role in the daily maintenance of muscle phenotype and function. 
 
Another work (Andrews JL, et al. 2010) reports that MyoD is a direct target of the circadian 
transcriptional activators CLOCK and BMAL1, which bind in a rhythmic manner to the core 
enhancer of the MyoD promoter (all of them resulted deregulated in our findings). Skeletal muscle 
of ClockΔ19 and Bmal1−/− mutant mice exhibited ∼30% reductions in normalized maximal force 
miming NMDs (Fig. 16).  
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Fig. 16: Altered expression of circadian genes in Clock mutant. Approximately 30% of the circadian genes in the Clock 
mutant showed a loss in cycling. Graphs comparing wild-type vs. Clock mutant expression (A–C) (Andrews J L et al. 
PNAS 2010;107:19090-19095) 
 
 
 
A similar reduction in force was observed at the single-fiber level. Electron microscopy (EM) 
showed that the myofilament architecture was disrupted in skeletal muscle of ClockΔ19, Bmal1−/−, 
and MyoD−/− mice. The alteration in myofilament organization was associated with decreased 
expression of actin, myosins, titin, and several MyoD target genes (Fig.17). 
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Fig 17. Decreased whole-muscle function and myofilament structure in ClockΔ19, Bmal−/−, and MyoD−/− mice. 
 
It is important to highlight that similar reduction in specific tension, and these deficits are very 
comparable to those observed in Duchenne muscular dystrophy and others NMDs such as collagen 
VI myopathies as well as those seen in aging (Gonzalez E, et al. 2000; Lynch GS, Et al. 2001). 
This suggests that the abnormalities observed in skeletal-muscle function might also be due to 
alterations in molecular clock function. The deficits recorded for whole-muscle tissue were also 
present at the single-cell level. These findings are consistent with the concept that proper function 
of the molecular clock in skeletal muscle fiber/cell is critical for maintenance of muscle function. 
 
EM analysis also demonstrated that muscle from both ClockΔ19 and Bmal1−/− mice had a 40% 
reduction in mitochondrial volume. The remaining mitochondria in these mutant mice displayed 
aberrant morphology characterized by swelling and disrupted cristae and increased uncoupling of 
respiration (Fig. 18).  
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Fig 18. Decreased mitochondrial volume and respiratory function in muscle of ClockΔ19 and Bmal1−/− mice. 
 
This result recapitulates the mitochondrial dysfunction found in mice with collagen VI deficiency 
(Irwin WA. et al. 2003) where authors have shown that Col6a1
-/-
 muscles have a loss of contractile 
strength associated with ultrastructural alterations of sarcoplasmic reticulum (SR) and mitochondria 
with abnormal cristae with tubular shape and altered matrix density associated with the presence of 
dense bodies. 
 
 
Taken together these results demonstrate that disruption of CLOCK or BMAL1 leads to structural 
and functional alterations at the cellular level in skeletal muscle. The identification of MyoD as a 
clock-controlled gene provides a mechanism by which the circadian clock may generate a muscle-
specific circadian transcriptome in an adaptive role for the daily maintenance of adult skeletal 
muscle. 
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CONCLUSIONS 
 
 
In conclusion evidence is growing that links inflammation, cancer, cardiovascular disease, sleep 
disorders, and metabolic disease with altered expression of the molecular clock in peripheral tissues 
(Duez H, et al. 2008. Maywood ES, et al. 2006. Takahashi JS, 2008). Thus, the significant force and 
metabolic deficits in the muscle of ClockΔ19 and Bmal1−/− mice, abnormal sarcoplasmic reticulum 
(SR) and mitochondria seen in Col6a1
-/- 
mice, and pathways involved in muscle regeneration, 
extracellular matrix remodeling and inflammation, can open the possibility that the profound 
peripheral weakness and fatigue seen in chronic diseases may also be the result from disruption of 
proper circadian factor expression in muscle. Therefore, circadian oscillators and proteins might 
represent molecular biomarkers measuring the muscle damage and impairment in COL6 
myopathies and other NMDs. Their strong link with environment opens also new avenues for novel 
therapeutic options. 
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